The older you get, the closer you are to death -an old Asian saying I n 1994-96, three studies described patients who had previously undergone coronary artery bypass graft surgery (CABG) and then had subsequent aortic valve replacement (AVR) (the aortic stenosis was "mild to moderate" at time of initial CABG); these patients were subsequently associated with a "high" operative mortality of 14-19%. [1] [2] [3] From these studies arose the rationale that patients who have mild to moderate aortic stenosis at the time of CABG will develop severe aortic stenosis within 10 years; such patients should therefore have combined CABG+AVR at time of initial bypass surgery. [1] [2] [3] There were several problems with this rationale, which have been previously described in detail and are summarised below. 4 x Two subsequent studies showed that the operative mortality for later AVR, if necessary, was not significantly diVerent from those undergoing CABG+AVR (0% and 7.7%).
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x Most importantly, these studies provided no information on the numbers of patients during the same time period who had mild to moderate aortic stenosis but did not require AVR during subsequent follow up.
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x There was little or no documentation to show that the aortic stenosis was mild to moderate at the time of the initial CABG. Moreover, some patients already had severe aortic stenosis at the time of initial CABG which was misdiagnosed. 4 x At time of subsequent AVR, the documentation showing that aortic stenosis was severe was sketchy. Many patients had angina as their symptom and 46-75% of these patients also needed repeat CABG at the time of late AVR. 4 x There was very little or no documentation of the patients' clinical condition at time of initial CABG and at the time of late AVR. At the time of late AVR some of the studies stated that many patients were in heart failure and New York Heart Association (NYHA) functional classes III and IV. 4 x The rate of progression of aortic stenosis, the manner of progression and whether it was linear or not, and factors determining more rapid progression were not fully known, especially in patients who had undergone CABG.
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Severity of aortic stenosis
Aortic stenosis is considered to be mild when the calculated aortic valve area (AVA) is > 1.5 cm 2 (table 1) . [8] [9] [10] [11] [12] An AVA < 1.0 cm 2 or an AVA index < 0.6 cm 2 /m 2 signify severe aortic stenosis. Reliance on gradients alone poses problems which have been previously described in detail. 4 The gradient across an aortic valve is related to flow across the valve in systole and is a "per beat", and not a "per minute", function.
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Thus, aortic valve gradient (AVG) is dependent on forward stroke volume from the left ventricle and systolic ejection time, both of which are a function of heart rate, and of left ventricular preload, afterload and myocardial contractility.
4 10 12 AVG is also dependent on the distal obstruction (systemic vascular resistance), and thus, on the pressure in the ascending aorta. 12 Therefore, AVGs can change from one minute to the next.
Measurement of gradients by Doppler ultrasound is clinically useful. However, their limitations must be kept in mind. Feigenbaum stated: "None of the echocardiographic techniques measures intravascular pressures directly." 13 The modified Bernoulli equation used to estimate gradients from Doppler velocities makes many assumptions, ignores several factors, and has been shown to be inaccurate in several subgroups. 4 Peak AVG by Doppler poses particular problems 4 and it is better to calculate mean AVG. In 636 patients studied by cardiac catheterisation over a 10 year period, no AVG (peak or mean) was found that was both sensitive and specific for severe aortic stenosis.
14 A mean gradient of > 50 mm Hg or a peak gradient of > 60 mm Hg were "specific" with a 90% or more positive predictive value. However, it was not possible to find a lower limit with 90% negative predictive value. The authors emphasised the importance of measuring AVA 14 in all patients with suspicion of severe aortic stenosis with a cardiac catheterisation mean AVG < 50 mm Hg (present in 50% of patients in their study) and a peak of < 60 mm Hg (present in 47% of patients in their study).
Patients with low mean AVG and reduced left ventricular ejection fraction (< 0. Mild > 1.5 > 1.5 > 1.5 > 0.9 Moderate 0.95-1.4 0.8-1.5 > 1.0-1.5 > 0.6-0.9 Severe < 0.9 < 0.8
Superscripts denote reference source. AVA, aortic valve area.
associated coronary artery disease; these patients therefore pose a more diYcult clinical problem. 12 However, they benefit from CABG+AVR, and thus there is a need for early diagnosis and surgery in such patients. 12 15 
Resolution of the problem
This clinical situation is more common in older patients (average age at time of initial CABG > 60 years) 4 and their mortality with or without surgery can be expected to be greater than in younger patients, especially if they have associated comorbid conditions. In the cited studies, late AVR was performed on average 8-9 years after the initial CABG. 4 Since there are no good prospective studies or trials addressing this clinical circumstance, one way to proceed is to: (1) determine the 10 year results of CABG+AVR; and (2) determine the 10 year results of isolated CABG and add to this the outcome of patients with mild to moderate aortic stenosis.
Mild aortic stenosis
Of two studies on the natural history of mild aortic stenosis (AVA > 1.5 cm 2 ) documented by cardiac catheterisation, one showed that by 10 years 8% of patients had developed severe aortic stenosis, 9 and in the other the event rate (which includes AVR plus mortality before and after AVR) was 15%.
8 Thus, it is likely that, at most, < 12% of survivors who initially did not have AVR will develop severe aortic stenosis; even if one assumes that the operative mortality of late AVR in these patients may be up to 15% (probably too high an estimate of mortality rate with modern surgical technique), the total
Results of CABG alone
x An operative (30 day) mortality of < 3% in those aged < 80 years and of >8.1% in those aged >80 years (table 2) [16] [17] [18] [19] x Many patients who undergo this operation will die from coronary artery disease, graft disease, graft occlusion, left ventricular dysfunction, and other comorbid conditions; approximately 30% at 10 years (table 3) 16 17 19 20 x A certain percentage will need repeat revascularisation for graft disease, graft occlusion, and progression of coronary artery disease-approximately 16% at 10 years.
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Results of CABG+AVR initially
x An average operative mortality of 7.9% in those aged < 80 years and of 10.6% in those > 80 years (table 2) x Many patients will die from coronary artery disease, graft disease, graft occlusion, left ventricular dysfunction, and other comorbid conditions, and the survivors will be subject to prosthesis related deaths-approximately 60% at 10 years (table 3) x A certain percentage will need repeat revascularisation for graft disease, graft occlusion, and progression of coronary artery disease-approximately 16% at 10 years. 16 x A significant percentage will have prosthesis related complications, including reoperation for prosthetic valve malfunction-up to approximately 2-6% per year. 21 22 Repeat revascularisation should be similar in both groups; its incidence and associated mortality are not included. Ten year complications after revascularisation and with prosthetic heart valves are not included. Mortality at time of reoperation are included in the 5 and 10 year data. The assumed 15% mortality for reoperation is probably too high. number of deaths from late AVR will be very small. Moreover, at the end of five years only 5% will need AVR.
If initially 100 patients had CABG+AVR, then at the end of 30 days, three years, and five years, the expected number of unnecessary AVRs would be 100, 100, and 95 and the number of excess deaths would be five, nine, and 14, respectively (table 4) .
At 10 years, to reduce one death from late AVR by a policy of AVR for mild aortic stenosis at time of initial CABG in 100 patients (table 4), the projected cumulative incidence of unnecessary AVR would be 91 and that of excess deaths would be 29, when compared to a policy of initial isolated CABG and later AVR if necessary (fig 1) . It should be noted that figures for reoperation, and mortality associated with reoperation, are included in the 10 year estimated outcome data in table 4 and fig 1.
Moderate aortic stenosis
The natural history of moderate aortic stenosis is more diYcult to estimate for a number of reasons. One study 8 provided information only on event-free survival which was 100% at the end of three years and 35% at the end of 10 years. Since all the events occurred in the intervening years, the event-free survival at five years can be expected to be about 81%. The event-free survival includes AVR plus mortality before and after AVR; the need for late AVR is not given separately.
8
A further study classified moderate aortic stenosis as an AVA of 0.8-1.5cm 2 . 9 However, another study has shown that the incidence of death and AVR in patients with "moderate" aortic stenosis (AVA of 0.7-1.2 cm 2 ) is 10% per year 23 ; many of these patients in fact had severe aortic stenosis, 9 23 -that is, AVA < 1.0 cm 2 (table 1) .
Other issues include the problem of assessing aortic stenosis progression, which has been extensively reviewed, 4 and the conflicting data over whether aortic stenosis in older patients progresses more rapidly than in younger *Mortality after CABG †Mortality after CABG+AVR ‡Events (death+AVR) at 10 years is 65%; for this analysis it was considered 65% of 70 survivors (that is, 46) would need late AVR which is most likely an overestimate. Repeat revascularisation similar in both groups; its incidence and associated mortality are not included. Ten year complications after revascularisation and with prosthetic heart valves are not included. Mortality at time of reoperation are included in the 5 and 10 year data. The assumed 15% mortality for reoperation is probably too high. x In patients with severe coronary artery disease and low mean AVG great care should be taken to ensure that severe aortic stenosis is not being misdiagnosed, especially in those in whom the left ventricular ejection fraction is reduced x Properly designed and carefully performed prospective studies are needed.
patients. 24 25 Thus, even if one assumes that 65% of the survivors who initially did not have AVR will develop severe aortic stenosis (an overestimate) and will need late AVR, and that the operative mortality of late AVR in these patients may be up to 15% (probably too high), the total number of deaths from late AVR will be quite small.
If initially, 100 patients had CABG+AVR, then at the end of 30 days, three years, and five years, the expected number of unnecessary AVRs would be 100, 100, and 85, and the number of excess deaths would be five, nine, and 13, respectively (table 5). It should be noted that the figures for reoperation, and mortality associated with reoperation, are included in the 10 year estimated outcome data in table 5 and fig 2. At 10 years, to reduce six deaths from late AVR by a policy of AVR for moderate aortic stenosis at time of initial CABG in 100 patients (table 5), the projected cumulative incidence of unnecessary AVR would be 54 and that of excess deaths would be 24 when compared to a policy of initial isolated CABG and later AVR if necessary (fig 2) .
In view of the uncertainty of the rate of progression of calcific aortic stenosis in older patients, at this time CABG for severe coronary artery disease plus AVR may be reasonable for moderate aortic stenosis with an AVA < 1.2 cm 2 and an AVA index < 0.8 cm 2 /m 2 in patients > 60-65 years of age, provided the patients are not at high risk for thromboembolism, 11 and thus can receive a biological valve (bioprosthesis). 11 22 In patients who initially had only CABG, at the time of subsequent AVR there is a risk of damage to internal mammary and vein grafts. Although this risk is small with appropriate care, and with skilled and experienced surgeons, it must be recognised this risk applies to reoperation in both subgroups (CABG and CABG+AVR). • A review detailing problems of the relevant studies, and assessment of severity and progression of aortic stenosis. Also presents suggested management of such patients. 7. Spodick DH. Revascularization of the heart numerators in search of denominators. Am Heart J 1971;81:149-57.
• An early article describing the problem of assessing patient outcome after treatment when the outcome of the total number of patients with that disorder is not known. • A study that details the natural history of all grades of aortic valve disease.
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